Semler Scientific, Inc., a company recognized for developing and marketing technology products and services to healthcare providers combating chronic diseases, disclosed its select preliminary unaudited financial results for the fourth quarter of 2024 in a press release issued on January 23, 2025.
According to the preliminary unaudited results, Semler Scientific reported revenues ranging between $12.1 million to $12.5 million for the fourth quarter of 2024. The company also highlighted income from operations estimated to be between $3.4 million to $3.7 million. Additionally, a remarkable unrealized gain from the change in the fair value of bitcoin holdings, amounting to approximately $28.9 million, was announced. As of December 31, 2024, Semler Scientific had cash, restricted cash, and cash equivalents totaling around $9.0 million.
CEO of Semler Scientific, Doug Murphy-Chutorian, M.D., expressed satisfaction with the preliminary unaudited numbers and highlighted the significant unrealized gain resulting from the company’s Bitcoin holdings. He also underscored the company’s commitment to executing its Bitcoin treasury strategy.
The preliminary unaudited financial data presented were based on Semler Scientific’s current expectations and could be subject to adjustments due to the completion of customary annual audit procedures. The final results may, therefore, diverge from the preliminary estimates as results are finalized.
Semler Scientific encourages individuals to participate in its Fourth Quarter and Full Year Financial Results Conference Call planned for February 18, 2025. This call will include updates on the company’s Bitcoin holdings. The conference call will be hosted by Dr. Murphy-Chutorian at 4:30 pm ET on the same day, alongside other key executives including Eric Semler, Renae Cormier, and Jennifer Oliva-Herrington.
Participants are encouraged to pre-register for the conference call via a provided link and submit questions in advance. Additionally, those unable to pre-register can join the call directly by dialing the specified numbers. The conference call will later be archived on Semler Scientific’s website.
This press release contains forward-looking statements about Semler Scientific’s unaudited financial results, Bitcoin holdings, and healthcare business, among other topics. These statements are subject to risks and uncertainties that could lead to variations in the company’s actual results. Semler Scientific advises that forward-looking statements are inherently uncertain and may differ from actual results.
Semler Scientific, Inc., known for its flagship product QuantaFlo® used in diagnosing cardiovascular diseases, is a frontrunner in offering technology solutions to healthcare providers. The company is also notable for investing in Bitcoin and adopting Bitcoin as its primary treasury asset. For further information, investors are encouraged to contact Chief Financial Officer Renae Cormier.
SOURCE: Semler Scientific, Inc.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Semler Scientific’s 8K filing here.
About Semler Scientific
Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.
Read More
- Five stocks we like better than Semler Scientific
- What Are Dividend Contenders? Investing in Dividend Contenders
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- How Can Investors Benefit From After-Hours Trading
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- With Risk Tolerance, One Size Does Not Fit All
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
